No Data
No Data
No Data
No Data
No Data
Donkey Trail Technology (01745) released its annual results, with a profit of 145 million yuan during the year, an increase of 286.7% over the previous year
Donkey Trail Technology (01745) announced its 2023 annual results, with revenue of 585 million yuan (RMB, same below), same as...
Zhitong FinanceMar 27 11:35 ET
LVJI TECH: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED DECEMBER 31, 2023
Futu NewsMar 27 10:44 ET · Announcements
Donkey Trail Technology (01745.HK) plans to hold a board meeting on March 27 to consider and approve the annual results
Gelonghui March 15 | Donkey Trail Technology (01745.HK) announced that the board meeting is scheduled to be held on March 27, 2024 (Wednesday) to (among others) approve the publication of the audited consolidated financial results of the Company and its subsidiaries for the year ended 31 December 2023 and consider the proposed payment of a final dividend (if any).
Gelonghui FinanceMar 15 05:07 ET
LVJI TECH: DATE OF BOARD MEETING
Futu NewsMar 15 04:44 ET · Announcements
Lvji Technology Unit Signs Deal For Stem Cell Preparation Research
Lvji Technology Holdings (HKG:1745) unit Lvji Technology Group has entered into a cooperation agreement with two parties for clinical application level research on umbilical cord mesenchymal stem cell
MT NewswiresMar 4 05:55 ET
Donkey Trail Technology (01745) subsidiary reached a scientific research project cooperation agreement with Guangdong Hospital of Traditional Chinese Medicine and other parties
Zhitong Financial App News, Donkey Trail Technology (01745) announced that Donkey Trail Technology Group Co., Ltd. (Donkey Trail Technology), an indirect wholly-owned subsidiary of the company, reached a cooperation agreement with Ark Frontier (Guangzhou) Health Management Company (Fangzhou Frontier) and Guangdong Provincial Hospital of Traditional Chinese Medicine/Stem Cell National Clinical Research Center (Guangdong Hospital of Traditional Chinese Medicine) to establish a clinical-grade umbilical cord mesenchymal stem cell formulation research agreement. According to the agreement, each contracting party jointly funded the application of a clinical-grade umbilical cord mesenchymal stem cell preparation under the name of the Guangdong Provincial Hospital of Traditional Chinese Medicine and obtained corresponding intellectual property rights and research results. The cooperation period is 24 months, as contracted by various parties
Zhitong FinanceMar 1 08:10 ET
No Data
No Data